MedTrace Logo

A Study of PBI-200 With Ritonavir or Cobicistat in Healthy Volunteers

NCT05692570 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2023-01-20

No results posted yet for this study

Summary

This is a drug-drug interaction study in volunteers to evaluate the effect of ritonavir or cobicistat on the pharmacokinetics (PK) of PBI-200.

Conditions

  • Drug-drug Interaction

Interventions

DRUG

PBI-200 Tablet

PBI-200 is a TRK inhibitor

DRUG

Ritonavir Oral Tablet

Ritonavir is a potent CYP3A inhibitor

DRUG

Cobicistat Oral Tablet

Cobicistat is a potent CYP3A inhibitor

Sponsors & Collaborators

  • Pyramid Biosciences

    lead INDUSTRY

Principal Investigators

  • Chief Medical Officer · Pyramid Biosciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-09-09
Primary Completion
2022-11-12
Completion
2022-11-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05692570 on ClinicalTrials.gov